The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations over 52 weeks by a relative 15.4% compared ...

Patients with chronic obstructive pulmonary disease (COPD) face a significant cardiovascular burden both before and after diagnosis. Analyses presented at the European Respiratory Society (ERS) ...

Biological therapy was associated with significant changes in lung structure and, by extension, improved lung function in ...

A new study published in The American Journal of Medicine found tirzepatide, which is prescribed for diabetes and weight ...

A phase 3 trial evaluating benralizumab for the treatment of COPD did not meet its primary endpoint, according to AstraZeneca.

Lucknow: A simple blood test every three months could save the lives of Chronic Obstructive Pulmonary Disease (COPD) patients ...

An EHR-embedded inpatient care pathway for COPD was tied to improved adherence to evidence-based practices, shorter hospital ...

Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial ...

C hronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition—primarily chronic bronchitis and ...

For decades, inhalers have been the cornerstone of COPD care. They improve symptoms and prolong life. But adherence is low — ...

Women face a higher risk of lung damage compared to men, even if they have never smoked. Research shows that biological ...

AstraZeneca’s RESOLUTE phase III trial of Fasenra to treat chronic obstructive pulmonary disease fails to meet primary endpoint: Cambridge, UK Thursday, September 18, 2025, 15:0 ...